[128] PEGINTERFERON o-2b AND RIBAVIRIN FOR 14 OR 24 WEEKS IN PATIENTS WITH HCV GENOTYPE 2 OR 3 AND RAPID VIROLOGICAL RESPONSE. THE NORTH-C TRIAL

33% (4112) PRC VS. 10% (1/10) PR patients (Figure I).PaR achieved EVR of 67% (6/9) for PR, while PRC group could not be evaluated.Safety.Celgosivir combination therapy was well tolerated and resulted in no significant adverse events.There was an increased frequency in mostly m l d diarrhea and flatulence in the celgosivir groups, while fatigue and flu-like symptoms were equally observed in all groups SVR rates in 227 Patients with RVR who received treatment Per protocol (group A, n='27, Group B, "=Io0)